Bluejay Diagnostics, Inc. (BJDX): Nasdaq/NYSE listing notice — Bluejay Diagnostics receives Nasdaq deficiency notice for bid price below $1.00

Bluejay Diagnostics, Inc.

Closing bid price below $1.00 for 30 consecutive business days; non-compliance with Nasdaq Listing Rule 5550(a)(2).
Company has 180 days, until August 26, 2024, to regain compliance by closing at $1.00+ for ten consecutive days.
If not cured, Company may be eligible for additional 180-day period, but delisting risk exists if unable to comply.
Company intends to take reasonable measures to regain compliance but no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bluejay Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 28, 2024, Bluejay Diagnostics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-019210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.